IBDEI0BQ ; ; 17-FEB-2016
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;JUN 29, 2015
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,5307,0)
 ;;=N03.6^^27^344^11
 ;;^UTILITY(U,$J,358.3,5307,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,5307,1,3,0)
 ;;=3^Chr nephritic syndrome w/ dense deposit disease
 ;;^UTILITY(U,$J,358.3,5307,1,4,0)
 ;;=4^N03.6
 ;;^UTILITY(U,$J,358.3,5307,2)
 ;;=^5015527
 ;;^UTILITY(U,$J,358.3,5308,0)
 ;;=N03.7^^27^344^12
 ;;^UTILITY(U,$J,358.3,5308,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,5308,1,3,0)
 ;;=3^Chr nephritic syndrome w/ diffuse crescentic glomrlneph
 ;;^UTILITY(U,$J,358.3,5308,1,4,0)
 ;;=4^N03.7
 ;;^UTILITY(U,$J,358.3,5308,2)
 ;;=^5015528
 ;;^UTILITY(U,$J,358.3,5309,0)
 ;;=N03.8^^27^344^19
 ;;^UTILITY(U,$J,358.3,5309,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,5309,1,3,0)
 ;;=3^Chr nephritic syndrome w/ other morphologic changes
 ;;^UTILITY(U,$J,358.3,5309,1,4,0)
 ;;=4^N03.8
 ;;^UTILITY(U,$J,358.3,5309,2)
 ;;=^5015529
 ;;^UTILITY(U,$J,358.3,5310,0)
 ;;=N03.9^^27^344^20
 ;;^UTILITY(U,$J,358.3,5310,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,5310,1,3,0)
 ;;=3^Chr nephritic syndrome w/ unsp morphologic changes
 ;;^UTILITY(U,$J,358.3,5310,1,4,0)
 ;;=4^N03.9
 ;;^UTILITY(U,$J,358.3,5310,2)
 ;;=^5015530
 ;;^UTILITY(U,$J,358.3,5311,0)
 ;;=N04.0^^27^344^60
 ;;^UTILITY(U,$J,358.3,5311,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,5311,1,3,0)
 ;;=3^Nephrotic syndrome w/ minor glomerular abnormality
 ;;^UTILITY(U,$J,358.3,5311,1,4,0)
 ;;=4^N04.0
 ;;^UTILITY(U,$J,358.3,5311,2)
 ;;=^5015531
 ;;^UTILITY(U,$J,358.3,5312,0)
 ;;=N04.1^^27^344^59
 ;;^UTILITY(U,$J,358.3,5312,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,5312,1,3,0)
 ;;=3^Nephrotic syndrome w/ focal & segmental glomerular lesions
 ;;^UTILITY(U,$J,358.3,5312,1,4,0)
 ;;=4^N04.1
 ;;^UTILITY(U,$J,358.3,5312,2)
 ;;=^5015532
 ;;^UTILITY(U,$J,358.3,5313,0)
 ;;=N04.2^^27^344^56
 ;;^UTILITY(U,$J,358.3,5313,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,5313,1,3,0)
 ;;=3^Nephrotic syndrome w/ diffuse membranous glomerulonephritis
 ;;^UTILITY(U,$J,358.3,5313,1,4,0)
 ;;=4^N04.2
 ;;^UTILITY(U,$J,358.3,5313,2)
 ;;=^5015533
 ;;^UTILITY(U,$J,358.3,5314,0)
 ;;=N04.3^^27^344^57
 ;;^UTILITY(U,$J,358.3,5314,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,5314,1,3,0)
 ;;=3^Nephrotic syndrome w/ diffuse mesangial prolif glomrlneph
 ;;^UTILITY(U,$J,358.3,5314,1,4,0)
 ;;=4^N04.3
 ;;^UTILITY(U,$J,358.3,5314,2)
 ;;=^5015534
 ;;^UTILITY(U,$J,358.3,5315,0)
 ;;=N04.4^^27^344^55
 ;;^UTILITY(U,$J,358.3,5315,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,5315,1,3,0)
 ;;=3^Nephrotic syndrome w/ diffuse endocaplry prolif glomrlneph
 ;;^UTILITY(U,$J,358.3,5315,1,4,0)
 ;;=4^N04.4
 ;;^UTILITY(U,$J,358.3,5315,2)
 ;;=^5015535
 ;;^UTILITY(U,$J,358.3,5316,0)
 ;;=N04.5^^27^344^58
 ;;^UTILITY(U,$J,358.3,5316,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,5316,1,3,0)
 ;;=3^Nephrotic syndrome w/ diffuse mesangiocapillary glomrlneph
 ;;^UTILITY(U,$J,358.3,5316,1,4,0)
 ;;=4^N04.5
 ;;^UTILITY(U,$J,358.3,5316,2)
 ;;=^5015536
 ;;^UTILITY(U,$J,358.3,5317,0)
 ;;=N04.6^^27^344^53
 ;;^UTILITY(U,$J,358.3,5317,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,5317,1,3,0)
 ;;=3^Nephrotic syndrome w/ dense deposit disease
 ;;^UTILITY(U,$J,358.3,5317,1,4,0)
 ;;=4^N04.6
 ;;^UTILITY(U,$J,358.3,5317,2)
 ;;=^5015537
 ;;^UTILITY(U,$J,358.3,5318,0)
 ;;=N04.7^^27^344^54
 ;;^UTILITY(U,$J,358.3,5318,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,5318,1,3,0)
 ;;=3^Nephrotic syndrome w/ diffuse crescentic glomerulonephritis
 ;;^UTILITY(U,$J,358.3,5318,1,4,0)
 ;;=4^N04.7
 ;;^UTILITY(U,$J,358.3,5318,2)
 ;;=^5015538
 ;;^UTILITY(U,$J,358.3,5319,0)
 ;;=N04.8^^27^344^61
 ;;^UTILITY(U,$J,358.3,5319,1,0)
 ;;=^358.31IA^4^2
